专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5286637A Biologically active drug polymer derivatives and method for preparing same 失效
标题翻译：生物活性药物聚合物衍生物及其制备方法
公开(公告)号：US5286637A
公开(公告)日：1994-02-15
申请号：US1434
申请日：1993-01-07
申请人： Francesco Veronese , Luciana Sartore , Piero Orsolini , Romano Deghenghi
发明人： Francesco Veronese , Luciana Sartore , Piero Orsolini , Romano Deghenghi
IPC分类号： A61K47/48 , C12P21/04 , C12N9/00 , A01N37/18 , C12P21/06
CPC分类号： A61K47/48215 , Y10S435/832
摘要： New biologically active drug polymer derivatives, namely peptides or protein derivatives, are useful medicaments and are represented by the generic formula:RO--(CH.sub.2 --CH.sub.2 O).sub.n --(CO)--NH--X--(CO)--NH--Z (I)whereinR represents a lower alkyl group,n is an integer comprised between 25 and 250,X when combined with adjacent NH and CO groups represents an amino acid or a dipeptide or tripeptide residue, andZ when combined with the adjacent NH group represents a biologically active peptide or protein or NH or NH.sub.2 containing drug residue.
摘要翻译： PCT No.PCT / EP90 / 01261 Sec。 371日期1991年6月3日 102（e）1991年6月3日PCT PCT 1990年7月26日PCT公布。公开号WO91 / 01758 日期：1991年2月21日。新的生物活性药物聚合物衍生物，即肽或蛋白质衍生物，是有用的药物，由以下通式表示：RO-（CH 2 -CH 2 O）n-（CO）-NH-X-（CO ）-NH-Z（I）其中R表示低级烷基，n是25至250之间的整数，当与相邻的NH和CO基团组合时，X代表氨基酸或二肽或三肽残基，当组合时，Z 相邻的NH基团代表生物活性肽或蛋白质或含NH或NH 2的药物残留物。

2. 发明授权

US4673595A Microencapsulation by phase separation of water-soluble medicaments 失效
标题翻译：通过相分离水溶性药物进行微胶囊化
公开(公告)号：US4673595A
公开(公告)日：1987-06-16
申请号：US787249
申请日：1985-10-15
申请人： Piero Orsolini , Rolland-Yves Mauvernay , Romano Deghenghi
发明人： Piero Orsolini , Rolland-Yves Mauvernay , Romano Deghenghi
IPC分类号： A61J3/07 , A61K9/16 , A61K9/36 , A61K9/50 , B01J13/20 , A61K9/52 , B01J13/02
CPC分类号： A61K9/1647 , A61K9/1694 , B01J13/206 , Y10T428/2989
摘要： The microencapsulation of medicamentous water-soluble substances is carried out by phase separation. The operations of the hardening step take place at a temperature comprised between about 0.degree. and about 25.degree. C., the non-solvent used during this step being an aliphatic fluorinated or fluorohalogenated hydrocarbon or a mixture of such hydrocarbons. Further, the non-solvent is used in an excess with respect to the volume of solvent and non-solvent resulting from the phase-separation step.
摘要翻译：药物水溶性物质的微囊化是通过相分离进行的。硬化步骤的操作在约0℃至约25℃的温度下进行，在该步骤中使用的非溶剂是脂族氟代或氟代卤代烃或这些烃的混合物。此外，相对于由相分离步骤得到的溶剂和非溶剂的体积，非溶剂的使用过量。

3. 发明授权

US5192741A Sustained and controlled release of water insoluble polypeptides 失效
标题翻译：水不溶性多糖的持续和控制释放
公开(公告)号：US5192741A
公开(公告)日：1993-03-09
申请号：US247060
申请日：1988-09-20
申请人： Piero Orsolini , Rolland-Yves Mauvernay , Romano Deghenghi
发明人： Piero Orsolini , Rolland-Yves Mauvernay , Romano Deghenghi
IPC分类号： A61K9/14 , A61K9/00 , A61K9/16 , A61K9/22 , A61K9/26 , A61K9/52 , A61K38/00 , A61K38/04 , A61K38/09 , A61K38/11 , A61K38/21 , A61K38/22 , A61K38/23 , A61K38/26 , A61K38/28 , A61K38/55 , A61K47/00 , A61K47/34
CPC分类号： A61K9/0024 , A61K38/04 , A61K38/09 , A61K9/1647
摘要： There is disclosed a pharaceutical composition for sustained and controlled release of drug over an extended period of time comprising a polylactide, a copolymer of lactic and glycolic acid, a mixture of such polymers and a water-insoluble peptide which, when placed in an aqueous physiologically-type environment releases the peptide in continuous manner for a period of at least one week, and with an initial release for the first twenty-four hours of not more than 30% of the total amount released. There is thus provided the control of the release pattern and in general a decrease of the initial burst effect.
摘要翻译：公开了一种药物组合物，其用于在延长的时间段内持续和控制释放药物，包括聚丙交酯，乳酸和乙醇酸的共聚物，这种聚合物的混合物和水不溶性肽，当将其置于水性生理学型环境以持续的方式释放肽至少一周的时间，第一个二十四小时的初次释放不超过释放总量的30％。因此，提供了释放模式的控制，并且通常降低了初始突发效应。

4. 发明授权

US5776885A Sustained and controlled release of water insoluble polypeptides 失效
标题翻译：水不溶性多肽的持续和受控释放
公开(公告)号：US5776885A
公开(公告)日：1998-07-07
申请号：US196872
申请日：1994-02-10
申请人： Piero Orsolini , Rolland-Yves Mauvernay , Romano Deghenghi
发明人： Piero Orsolini , Rolland-Yves Mauvernay , Romano Deghenghi
IPC分类号： A61K9/14 , A61K9/00 , A61K9/16 , A61K9/22 , A61K9/26 , A61K9/52 , A61K38/00 , A61K38/04 , A61K38/09 , A61K38/11 , A61K38/21 , A61K38/22 , A61K38/23 , A61K38/26 , A61K38/28 , A61K38/55 , A61K47/00 , A61K47/34
CPC分类号： A61K9/0024 , A61K38/04 , A61K38/09 , A61K9/1647
摘要： A pharmaceutical composition for the sustained release of a peptide wherein the composition includes a polylactide polymer, a polymer of lactic acid and glycolic acid, or a mixture of such polymers and a therapeutically active peptide in the form of its pamoate, tannate or stearate salt. The composition when placed in an aqueous physiological environment releases the peptide in a continuous manner for a period of at least about one week.
摘要翻译：用于持续释放肽的药物组合物，其中所述组合物包含聚丙交酯聚合物，乳酸和乙醇酸的聚合物，或这些聚合物的混合物和其双羟萘酸盐，鞣酸盐或硬脂酸盐形式的治疗活性肽。当置于水性生理环境中时，组合物以连续方式释放肽至少约一周的时间。

5. 发明授权

US07098305B2 Sustained release of microcrystalline peptide suspensions 有权
公开(公告)号：US07098305B2
公开(公告)日：2006-08-29
申请号：US10080130
申请日：2002-02-19
申请人： Romano Deghenghi , Francois Boutignon
发明人： Romano Deghenghi , Francois Boutignon
IPC分类号： A61K38/00 , A61K38/04 , C07K5/00 , C07K7/00 , C07K16/00
CPC分类号： A61K9/0024 , A61K9/0019 , A61K9/10 , A61K9/19 , A61K38/09 , A61K38/31 , A61K47/02 , A61K47/12 , A61K47/20 , A61K47/26
摘要： The invention relates to a method of preventing gel formation of a hydrophobic peptides by contacting the hydrophobic peptide with a counter-ion in an amount and at a molar ratio with the peptide that are sufficient to provide a fluid, milky microcrystalline aqueous suspension of the peptide without formation of a gel. The invention also relates to a fluid, milky microcrystalline aqueous suspension of a hydrophobic peptide and a counter-ion in water, wherein the peptide and counter-ion are present in amounts and at a molar ratio sufficient to form, upon mixing, the suspension without formation of a gel.

6. 发明授权

US06211156B1 Peptides for treatment of erectile dysfunction 失效
标题翻译：用于治疗勃起功能障碍的肽
公开(公告)号：US06211156B1
公开(公告)日：2001-04-03
申请号：US09437147
申请日：1999-11-10
申请人： Antonio Argiolas , Romano Deghenghi
发明人： Antonio Argiolas , Romano Deghenghi
IPC分类号： A61K3805
CPC分类号： C07K7/06 , A61K38/07 , A61K38/08 , C07K5/0205 , C07K7/02
摘要： The present invention relates to small peptides that cause penile erections in male animals when injected into the paraventricular nucleus of the hypothalamus or when given systemically (intravenously or subcutaneously) to such animals. These peptides are useful in the treatment of erectile dysfunction.
摘要翻译：本发明涉及当注射到下丘脑的室旁核中时或当全身（静脉内或皮下）给予这些动物时，引起雄性动物阴茎勃起的小肽。这些肽可用于治疗勃起功能障碍。

7. 发明授权

US5962409A Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone 失效
标题翻译：具有生长激素抑制活性的生长抑素类似环肽
公开(公告)号：US5962409A
公开(公告)日：1999-10-05
申请号：US983363
申请日：1998-01-14
申请人： Romano Deghenghi
发明人： Romano Deghenghi
IPC分类号： A61K38/00 , A61K31/00 , A61K51/00 , A61P5/00 , A61P5/08 , A61P35/00 , C07K14/655 , A61K38/31
CPC分类号： C07K14/6555 , A61K38/00
摘要： Cyclic peptides of general formula (I), wherein the groups are as described in the disclosure, having inhibitory activity on growth hormone. The peptides of formula (I) have also anticancer activity. ##STR1##
摘要翻译： PCT No.PCT / EP96 / 03149 371日期：1998年1月14日 102（e）1998年1月14日PCT PCT 1996年7月17日PCT公布。第WO97 / 05167号公报日期1997年2月13日通式（I）的环肽，其中基团如本公开所述，对生长激素具有抑制活性。式（I）的肽也具有抗癌活性。

8. 发明授权

US08415300B2 Sustained release of microcrystalline peptide suspensions 有权
标题翻译：微晶肽悬浮液的持续释放
公开(公告)号：US08415300B2
公开(公告)日：2013-04-09
申请号：US13224105
申请日：2011-09-01
申请人： Romano Deghenghi , Francois Boutignon
发明人： Romano Deghenghi , Francois Boutignon
IPC分类号： A61K38/09 , A61K38/00 , A61K38/08 , A61P43/00 , C07K2/00 , C07K7/06
CPC分类号： A61K9/0024 , A61K9/0019 , A61K9/10 , A61K9/19 , A61K38/09 , A61K38/31 , A61K47/02 , A61K47/12 , A61K47/20 , A61K47/26
摘要： A fluid, milky microcrystalline aqueous suspension of a peptide or peptidomimetic and a counter-ion of a strong proton donor in water, wherein the peptide or peptidomimetic and counter-ion are present in amounts and at a molar ratio sufficient to form the suspension upon mixing and without formation of a gel. Also, lyophilized compositions that include a dried suspension, methods of making the lyophilized composition, methods of preparing the suspension, and sustained release formulations prepared by the methods.
摘要翻译：肽或肽模拟物的流体，乳状微晶水悬浮液和强质子供体在水中的抗衡离子，其中肽或拟肽和抗衡离子以足以在混合时形成悬浮液的量和摩尔比存在并且不形成凝胶。此外，包括干燥悬浮液的冻干组合物，制备冻干组合物的方法，制备悬浮液的方法以及通过该方法制备的缓释制剂。

9. 发明授权

US6159490A Implants containing bioactive peptides 失效
标题翻译：植入物含有生物活性肽
公开(公告)号：US6159490A
公开(公告)日：2000-12-12
申请号：US543707
申请日：2000-04-05
申请人： Romano Deghenghi
发明人： Romano Deghenghi
IPC分类号： A61K9/00 , A61K9/20 , A61K38/00 , A61K47/34 , A61F2/02 , B01J13/02 , B01J13/04 , A61F9/50
CPC分类号： A61K9/0024 , A61K9/204 , A61K9/2095
摘要： A pharmaceutical implant for the delivery of an effective amount of a bioactive peptide or peptide analog over a period of 1 to 12 months. This implant has a diameter of about 1 to 2 mm, a length of between about 10 and 25 mm and is obtainable from a process which includes the steps of grinding a copolymer of lactic acid and glycolic acid having a ratio of glycolide to lactide units of from about 0 to 5:1 to a particle size of between about 50 and 150 .mu.m; sterilizing the ground copolymer with a dose of between about 1 and 2.5 Mrads of ionizing .gamma.-radiation; wetting the ground and sterilized copolymer with a sterile aqueous slurry of a bioactive peptide or peptide analog; aseptically blending the copolymer and the slurry to obtain a homogeneous mixture of the copolymer and between about 10 and 50% of the bioactive peptide or peptide analog; drying the mixture at reduced pressure and at temperature not exceeding 25.degree. C.; aseptically extruding the dried mixture at a temperature between about 70 and 110.degree. C.; and aseptically cutting a cylindrical rod from the extruded mixture to form the pharmaceutical implant.
摘要翻译：用于在1至12个月的时间内递送有效量的生物活性肽或肽类似物的药物植入物。该植入物的直径为约1-2mm，长度在约10-25mm之间，可通过以下步骤获得，该方法包括以下步骤：将具有乙交酯与丙交酯单元的比例的乳酸和乙醇酸的共聚物约0至5:1至约50至150μm的粒度; 以约1至2.5Mrad的电离γ辐射剂量灭菌研磨共聚物; 用生物活性肽或肽类似物的无菌水性浆液润湿研磨和灭菌的共聚物; 无菌混合共聚物和浆料以获得共聚物的均匀混合物和约10至50％的生物活性肽或肽类似物; 在减压和不超过25℃的温度下干燥混合物。在约70至110℃的温度下无菌挤出干燥的混合物; 并从挤出的混合物无菌切割圆柱形杆以形成药物植入物。

10. 发明授权

US6077523A Process to manufacture implants containing bioactive peptides 失效
标题翻译：制造含有生物活性肽的植入物的方法
公开(公告)号：US6077523A
公开(公告)日：2000-06-20
申请号：US311744
申请日：1999-05-14
申请人： Romano Deghenghi
发明人： Romano Deghenghi
IPC分类号： A61K9/00 , A61K9/20 , A61K38/00 , A61K47/34 , A61F2/02 , A61K9/50 , B01J13/02
CPC分类号： A61K9/0024 , A61K9/204 , A61K9/2095
摘要： A pharmaceutical implant for the delivery of an effective amount of a bioactive peptide or peptide analog over a period of 1 to 12 months. This implant has a diameter of about 1 to 2 mm, a length of between about 10 and 25 mm and is obtainable from a process which includes the steps of grinding a copolymer of lactic acid and glycolic acid having a ratio of glycolide to lactide units of from about 0 to 5:1 to a particle size of between about 50 and 150 .mu.m; sterilizing the ground copolymer with a dose of between about 1 and 2.5 Mrads of ionizing .gamma.-radiation; wetting the ground and sterilized copolymer with a sterile aqueous slurry of a bioactive peptide or peptide analog; aseptically blending the copolymer and the slurry to obtain a homogeneous mixture of the copolymer and between about 10 and 50% of the bioactive peptide or peptide analog; drying the mixture at reduced pressure and at temperature not exceeding 25.degree. C.; aseptically extruding the dried mixture at a temperature between about 70 and 110.degree. C.; and aseptically cutting a cylindrical rod from the extruded mixture to form the pharmaceutical implant.
摘要翻译：用于在1至12个月的时间内递送有效量的生物活性肽或肽类似物的药物植入物。该植入物的直径为约1-2mm，长度在约10-25mm之间，可通过以下步骤获得，该方法包括以下步骤：将具有乙交酯与丙交酯单元的比例的乳酸和乙醇酸的共聚物约0至5:1至约50至150μm的粒度; 以约1至2.5Mrad的电离γ辐射剂量灭菌研磨共聚物; 用生物活性肽或肽类似物的无菌水性浆液润湿研磨和灭菌的共聚物; 无菌混合共聚物和浆料以获得共聚物的均匀混合物和约10至50％的生物活性肽或肽类似物; 在减压和不超过25℃的温度下干燥混合物。在约70至110℃的温度下无菌挤出干燥的混合物; 并从挤出的混合物无菌切割圆柱形杆以形成药物植入物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式